MEDICLIN (MED) AI Stock Analysis

• Market Cap: €176.70M
• Dividend Yield: 1.12%
• Average Volume (3M): 5.25K
• Price to Earnings (P/E): 5.0
• Beta (1Y): 0.20
• Revenue Growth: 4.90%
• EPS Growth: N/A
• Country: DE
• Employees: 7,292
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Care Facilities
• EPS (TTM): 0.32
• Shares Outstanding: 47,500,000
• 10 Day Avg. Volume: 4,347
• 30 Day Avg. Volume: 5,253
• PEG Ratio: -0.01
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 0.15
• P/FCF Ratio: 3.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 77 Outperform
• Price Target: €4.00 ▲(11.11% Upside)

MEDICLIN's stock is rated positively due to its strong technical indicators and attractive valuation. The financial performance shows solid growth and efficiency, though high leverage is a concern. The absence of earnings call data and corporate events does not impact the score significantly.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for MEDICLIN's services and suggests a robust market position in the healthcare sector.

Operational Efficiency

Strong gross profit margins reflect effective cost control, which enhances profitability and supports long-term financial health.

Cash Flow Stability

Improved operating cash flow enhances financial stability, ensuring MEDICLIN can meet obligations and invest in growth opportunities.

Negative Factors

High Leverage

High leverage can increase financial risk, potentially limiting MEDICLIN's ability to invest in growth or weather economic downturns.

Low Net Profit Margin

A low net profit margin indicates challenges in converting revenue into profit, which could impact long-term financial performance.

Moderate Cash Conversion Efficiency

Moderate cash conversion efficiency may hinder MEDICLIN's ability to generate cash from its operations, affecting liquidity and investment capacity.

MEDICLIN Business Overview & Revenue Model

Company Description

MEDICLIN Aktiengesellschaft operates hospitals in Germany. The company operates through Post-Acute, Acute, and Other Activities segments. It offers medical services in the areas of neurology, psychosomatics, orthopaedics, internal medicine, cardiology, oncology, geriatrics, psychiatry, surgery, nursing care, and others. The company also provides services in the areas of ENT and acute outpatient services. As of December 31, 2021, it owned 34 clinics, 7 nursing care facilities, and 11 medical care centres with a total capacity of 7,831 beds and 482 nursing places in 11 German federal states. The company is headquartered in Offenburg, Germany.

How the Company Makes Money

MEDICLIN generates revenue primarily through its healthcare services, which include inpatient and outpatient care, surgical procedures, and diagnostic services. The company charges patients and insurance companies for these services, establishing a diverse revenue stream. Additionally, MEDICLIN may have partnerships with insurance providers that allow for negotiated rates, further enhancing its earnings potential. The company might also engage in contract agreements with government health programs, providing additional stability to its revenue model. Furthermore, MEDICLIN could benefit from ancillary services such as rehabilitation, pharmacy, and medical equipment sales, contributing to its overall financial performance.

MEDICLIN Financial Statement Overview

Summary

MEDICLIN shows solid revenue and profit growth with strong gross margins. However, high leverage poses financial risks despite improving profitability metrics. Strong cash flow generation is noted, though conversion of earnings to free cash flow could be better.

Income Statement

MEDICLIN has shown consistent revenue growth with a TTM revenue growth rate of 2.20%. The gross profit margin is strong at 83.59%, indicating efficient cost management. Net profit margin improved to 3.49% TTM, reflecting enhanced profitability. However, the EBIT and EBITDA margins, while stable, suggest room for operational efficiency improvements.

Balance Sheet

The company maintains a high debt-to-equity ratio of 2.09 TTM, indicating significant leverage, which could pose financial risks. Return on equity improved to 12.59% TTM, showing better utilization of equity. The equity ratio is moderate, suggesting a balanced asset structure but with potential vulnerability due to high debt levels.

Cash Flow

MEDICLIN's free cash flow growth rate is robust at 26.84% TTM, demonstrating strong cash generation capabilities. The operating cash flow to net income ratio is 0.47, indicating adequate cash flow relative to earnings. However, the free cash flow to net income ratio of 0.44 suggests that not all earnings are translating into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	764.62M	748.80M	730.10M	704.70M	673.10M	659.90M
Gross Profit	641.99M	623.00M	594.60M	571.90M	551.00M	547.20M
EBITDA	117.77M	106.41M	101.27M	91.80M	85.43M	76.84M
Net Income	33.96M	24.84M	-10.78M	9.44M	1.46M	-9.00M
Balance Sheet
Total Assets	902.37M	905.91M	880.50M	916.11M	881.24M	887.46M
Cash, Cash Equivalents and Short-Term Investments	110.19M	107.56M	115.29M	88.04M	133.48M	100.44M
Total Debt	455.32M	464.13M	479.82M	502.67M	439.96M	486.97M
Total Liabilities	670.10M	683.17M	684.47M	706.79M	698.22M	710.62M
Stockholders Equity	231.86M	222.51M	195.92M	209.21M	183.28M	177.16M
Cash Flow
Free Cash Flow	43.38M	35.88M	40.43M	8.62M	64.96M	92.91M
Operating Cash Flow	93.20M	80.57M	78.00M	34.64M	81.97M	118.69M
Investing Cash Flow	-31.34M	-15.13M	-9.51M	-6.24M	-7.09M	-8.60M
Financing Cash Flow	-75.26M	-73.16M	-45.48M	-56.17M	-55.26M	-46.50M

MEDICLIN Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MED, the sentiment is Positive. The current price of 3.6 is below the 20-day moving average (MA) of 3.66, above the 50-day MA of 3.59, and above the 200-day MA of 3.16, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 57.62 is Neutral, neither overbought nor oversold. The STOCH value of 61.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:MED.

MEDICLIN Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MED	77 Outperform	€176.70M	5.04	15.25%	1.12%	4.90%	―
M12	74 Outperform	€346.29M	19.39	15.61%	2.80%	6.52%	7.17%
LIK	73 Outperform	€109.80M	23.85	23.66%	―	0.21%	7.53%
RHK	70 Outperform	€863.51M	22.66	2.94%	0.77%	9.10%	-15.07%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
MAK	41 Neutral	€20.66M	-1.55	―	―	6.87%	-94.85%